Tìm theo
Gadopentetate dimeglumine
Các tên gọi khác (6 ) :
  • Diethylenetriaminepentaacetic acid dimeglumine salt gadolinium chelate
  • Dimeglumine-gadolinium-dtpa
  • Gadopentetic acid dimeglumine salt
  • Gd-DTPA
  • Magnevist
  • Meglumine gadopentetate
contrast media
Thuốc Gốc
Small Molecule
CAS: 86050-77-3
ATC: V08CA01
ĐG : Bayer Healthcare , http://www.bayerhealthcare.com
CTHH: C28H54GdN5O20
PTK: 938
A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C28H54GdN5O20
Phân tử khối
938
Monoisotopic mass
938.260314726
InChI
InChI=1S/C14H23N3O10.2C7H17NO5.Gd/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27;2*1-8-2-4(10)6(12)7(13)5(11)3-9;/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27);2*4-13H,2-3H2,1H3;/q;;;+3/p-3/t;2*4-,5+,6+,7+;/m.00./s1
InChI Key
InChIKey=LGMLJQFQKXPRGA-VPVMAENOSA-K
IUPAC Name
gadolinium(3+) ion bis((2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol) 2-[bis({2-[(carboxylatomethyl)(carboxymethyl)amino]ethyl})amino]acetate
Traditional IUPAC Name
gadolinium(3+) H2dtpa bis(meglumine)
SMILES
[Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN(CCN(CCN(CC(O)=O)CC([O-])=O)CC([O-])=O)CC([O-])=O
logP
-6.4
pKa (strongest acidic)
0.094
pKa (Strongest Basic)
9.59
PSA
204.71 Å2
Refractivity
118.96 m3·mol-1
Polarizability
34.17 Å3
Rotatable Bond Count
28
H Bond Acceptor Count
13
H Bond Donor Count
2
Physiological Charge
-4
Number of Rings
0
Bioavailability
0
Cơ Chế Tác Dụng : A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. The proton relaxation effect (PRE) of an unpaired electron is 700 times stronger than that of a proton itself. In MRI, visualization of normal and pathological brain tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadopentetate dimeglumine shortens the T1 and T2 relaxation times in tissues where it accumulates. In the central nervous system (CNS), gadopentetate dimeglumine enhances visualization of normal tissues that lack a blood-brain barrier, such as the pituitary gland and the meninges. Gadopentetate dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadopentetate dimeglumine in lesions such as neoplasms, abscesses, and subacute infarcts. Outside the CNS, gadopentetate dimeglumine rapidly reaches equilibrium in the interstitial compartment and enhances signal in all tissues as a function of delivery and size of the interstitial compartment. This compound has also been found to inhibit human erythrocyte 6-phosphogluconate dehydrogenase.
Dược Động Học :

▧ Volume of Distribution :
* 266 ± 43 mL/kg
▧ Metabolism :
No detectable biotransformation or decomposition.
▧ Route of Elimination :
Gadopentetate is exclusively eliminated in the urine with 83 ± 14% (mean ± SD) of the dose excreted within 6 hours and 91 ± 13% (mean ± SD) by 24 hours, post-injection.
▧ Half Life :
Distribution half life 12 minutes, elimination half 100 minutes
▧ Clearance :
* 1.94 +/- 0.28 mL/min/kg [Normal subjects]
Chỉ Định : For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Liều Lượng & Cách Dùng : Liquid - Intravenous
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Magnevist vial
    Giá bán buôn : USD >5.54
    Đơn vị tính : ml
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00789
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=55466
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504878
KEGG Drug
http://www.genome.jp/dbget-bin/www_bget?drug:D01707
ChemSpider
http://www.chemspider.com/Chemical-Structure.50087.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/50419-188-58
PharmGKB
http://www.pharmgkb.org/drug/PA164748760
Wikipedia
http://en.wikipedia.org/wiki/Gadopentetate_dimeglumine
RxList
http://www.rxlist.com/cgi/generic4/magnevist.htm
Drugs.com
http://www.drugs.com/cdi/gadopentetate-dimeglumine.html
... loading
... loading